SWM
VIR icon

Salvus Wealth Management’s Vir Biotechnology VIR Stock Holding History

Salvus Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,691
Closed -$70.5K – 142
2025
Q4 		$70.5K Hold
11,691
– – 0.04% 132
2025
Q3 		$66.8K Hold
11,691
– – 0.04% 129
2025
Q2 		$58.9K Hold
11,691
– – 0.03% 121
2025
Q1 		$75.8K Hold
11,691
– – 0.05% 116
2024
Q4 		$85.8K Hold
11,691
– – 0.05% 113
2024
Q3 		$87.6K Hold
11,691
– – 0.05% 112
2024
Q2 		$104K Hold
11,691
– – 0.07% 106
2024
Q1 		$118K Hold
11,691
– – 0.08% 102
2023
Q4 		$118K Hold
11,691
– – 0.08% 104
2023
Q3 		$110K Buy
+11,691
New +$167K 0.09% 100

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Salvus Wealth Management's VIR Position: Q1 2026 in Review

Salvus Wealth Management sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 11,691 shares — an estimated $70.5K sold.

Salvus Wealth Management first reported a position in VIR in Q3 2023 and held it in 10 quarters. The position peaked at $118K in Q1 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Salvus Wealth Management reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Salvus Wealth Management sold 11,691 Vir Biotechnology shares in Q1 2026, an estimated $70.5K.
  • Salvus Wealth Management first reported a position in Vir Biotechnology in Q3 2023 and held it in 10 quarters.
  • Salvus Wealth Management's Vir Biotechnology position peaked at $118K in Q1 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Salvus Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.